Boundless Bio, Inc.

NASDAQ:BOLD

Biotechnology

Healthcare
$2.40 +85.71%

+$1.20 today

Market cap
$56.67M
Beta
0.97
P/E (TTM)
-1.0
EPS (TTM)
-$2.50
52W Low $0.96High $2.75

Volume 0.15M

Average 0.22M

BOLD Depreciation & Amortization

Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.

Boundless Bio, Inc.NASDAQ: BOLD

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization dips below year-ago levels

Q1 FY2026 depreciation & amortization of $284K fell 10.4% year over year, behind the +6.8% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 7.5% from the prior quarter. Over 3 fiscal years it compounded at +9.9% a year.

Context

  • Depreciation & amortization increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -10.4% toward the trailing-twelve-month pace of +6.8%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$284K-7.5% QoQ
Last fiscal yearDec 2025
$1.25M+15.2% YoY
LTMMar 2026
$1.22M+6.8% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-10.4%——
1 year+15.2%——
3-year CAGR+9.9%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the income statement

Latest · FY2025
1.25M USD
Year-over-year change
+15.2%
4-year CAGR
+16.4%

Depreciation & Amortization vs competitors

How BOLD compares with its peers on the latest reported figures

  • BOLD's LTM Mar 2026 depreciation & amortization of $1.22M is the highest of the 4 companies compared; the peer median is $67K.
  • Its year-over-year change of +6.8% is the highest of 4, against a peer median of -46.0%.
  • Over three fiscal years its annual growth of +9.9% compares with a peer median of -8.1%.
BOLD Competitors Peer median
Depreciation & Amortization for BOLD and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BOLDBoundless Bio, Inc.LTM Mar 2026$1.22M +6.8%+9.9%—
QTTBQ32 Bio Inc.LTM Mar 2026$362K -25.1%+1.9%0.7%
RLYBRallybio CorporationLTM Mar 2026$67K -46.0%-18.0%7.8%
ANTXAN2 Therapeutics, Inc.LTM Mar 2026$0 -100.0%——
Peer median (excluding BOLD) $67K-46.0%-8.1%4.2%

Competitors are the stored peer set for BOLD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue0001.09M1.25M
Gross Profit000(1.09M)(1.25M)
Gross Margin—————
Research & Development19.28M37.16M42.64M55.27M44.85M
Selling, General & Admin6.02M9.31M12.16M18M18.71M
Operating Expenses25.3M46.47M54.8M72.18M62.3M
Depreciation & Amortization682K942K957K1.09M1.25M
EBITDA(24.53M)(44.96M)(48.48M)(64.28M)(56.95M)
EBITDA Margin—————
Operating Income(25.3M)(46.47M)(54.8M)(73.27M)(63.55M)
Operating Margin—————
Interest Income96K668K5.28M7.89M5.36M
Interest Expense00000
Other Income / Expenses91K568K5.36M7.9M5.36M
Income Before Tax(25.21M)(45.9M)(49.43M)(65.36M)(58.2M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(25.21M)(45.9M)(49.43M)(65.36M)(58.2M)
Net Margin—————
EPS (Basic)(1.13)(2.06)(2.22)(3.85)(2.60)
EPS (Diluted)(1.13)(2.06)(2.22)(3.85)(2.60)
Weighted Avg Shares22.24M22.24M22.24M16.98M22.36M
Weighted Avg Shares (Diluted)22.24M22.24M22.24M16.98M22.36M

Boundless Bio, Inc.

NASDAQ:BOLD

Intrinsic Alpha fair value

Locked

Current Price

$2.40

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.